Cost Effectiveness of Rifaximin-Á 550mg In The Reduction of Recurrence of Overt Hepatic Encephalopathy In United Kingdom.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Value in Health

• Publication date

  2015-11-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1016/j.jval.2015.09.2206PMID 26533513
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin

  2018cites this paper
• Design of the Prospective Real-world Outcomes Study of hepatic encephalopathy Patients’ Experience on Rifaximin-α (PROSPER): an observational study among 550 patients

  2018cites this paper
• Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy

  2017cites this paper
• Recent advances in hepatic encephalopathy

  2017cites this paper